Managing patients with EGFR exon 20 ins in NSCLC and EGFR TKI toxicity

Treatments for patients with NSCLC carrying EGFR exon 20 insertionsПодробнее

Panel Discussion: Challenges and Opportunities to Managing EGFR Exon 20 MutationsПодробнее

EGFR Exon 20 Mutations in Non–Small Cell Lung CancerПодробнее

Latest in EGFR-positive NSCLC with exon 20 insertion mutationsПодробнее

From clinic to practice in NSCLC patients with exon 20 mutationsПодробнее

Dr. Gitlitz on EGFR Exon 20 Insertion Mutations in Lung CancerПодробнее

Panel Discussion: Case Studies in Managing Patients with EGFR Exon 20 MutationsПодробнее

Exon 20 insertions in NSCLC - ESMO 2020Подробнее

Treating Non–Small Cell Lung Cancer With an EGFR Exon 20 InsertionПодробнее

The evolving treatment landscape for NSCLC with EGFR exon 20 insertion mutationsПодробнее

ZENITH20: poziotinib in EGFR and HER2 Exon 20 mutant NSCLCПодробнее

NSCLC With EGFR Exon 20 Shows Benefit With Mobocertinib Over ChemotherapyПодробнее

A Visual Exploration of New Targeted Therapies for EGFR Exon 20 Insertions in NSCLCПодробнее

Current treatments and challenges for patients with EGFR exon 20 insertion-positive NSCLCПодробнее

Targeted treatments for EGFR exon 20 insertion mutations in NSCLCПодробнее

Personalizing Therapy for EGFR Exon 20-Mutant NSCLCПодробнее

Real world data and diagnostics in patients with NSCLC with EGFR exon 20 insertionsПодробнее

Targeted Therapy in EGFR Exon 20-Mutant Non–Small Cell Lung CancerПодробнее

Panel Discussion: Managing Patients with Acquired EGFR ResistanceПодробнее